Treatment-emergent weight gain has been reported in younger patients receiving atypical antipsychotics, but less is known about weight gain in adults aged 65 years and older. This was a post hoc analysis of 1267 patients with dementia and behavioral disturbances treated with olanzapine (1 to 20 mg/d) in clinical trials, most of whom were underweight (body mass index <18.5 kg/m2) or of normal weight (body mass index, 18.5-24.9 kg/m2) at baseline. Weight changes over the first 20 weeks of treatment in olanzapine-treated patients, as estimated by a repeated measures analysis model, were significantly greater in the combined categories of underweight and normal weight (1.22 kg and 1.29 kg, respectively) versus overweight and obese (0.56 kg and 0.53 kg, respectively; P = .006). The estimated probability of gaining more than 7% of initial body weight was significantly greater in patients treated with olanzapine versus active comparator (P < .001) or placebo (P < .001). Weight gain in olanzapine-treated older patients with dementia and behavioral disturbances was significantly greater in individuals with a baseline body mass index of less than 25 kg/m2. (J Geriatr Psychiatry Neurol 2007;20:107-114)
Alexopolous GS, Streim J., Carpenter D., et al. Using antipsychotic agents in older patients. J Clin Psychiatry.2004; 65(suppl 2):5-99.
2.
Bullock R.Treatment of behavioral and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin.2005;21:1-10.
3.
FDA Public Health Advisory, April 11, 2005 . Available at: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm . Accessed April 19, 2005.
4.
Gill SS, Rochon PA, Herrmann N., et al. Atypical antipsychotics drugs and risk of ischaemic stroke: population base retrospective cohort study. BMJ.2005;330:445.
5.
Hartikainen S., Rahkonen T., Kautiainen H., Sulkava R.The use of psychotropics and survival in demented elderly individuals. Int Clin Psychopharmacol.2005;20:227-231.
6.
Sink KM, Holden KF, Yaffe K.Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA.2005;293:596-608.
7.
Brodaty H., Ames D., Snowdon J., et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry.2003; 64:134-143.
8.
Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia . Int J Geriatr Psychiatry. 2001;16(suppl 1):S62-S70.
9.
Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry . 2000;57:968-976.
10.
Tariot PN, Salzman C., Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther.2000;22:1068-1084.
11.
Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry.1999;60:107-115.
12.
Allison DB, Casey DEAntipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry.2001;62(suppl 7): 22-31.
13.
Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GDFactors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry.2001;62:231-238.
14.
Lipkovich I. , Citrome L., Perlis R., Deberdt W., Houston JP, Ahl J., Hardy T.Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol.2006;26:316-320.
15.
Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia . Am J Geriatr Psychiatry. 2005;13:722-730.
16.
De Deyn PP, Carrasco MM, Deberdt W., et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry.2004;19:115-126.
17.
Gurevitz SL , Costakis T., Leiter J.Do atypical antipsychotics cause weight gain in nursing home dementia residents? Consult Pharm.2004;19:809-812.
18.
Lasser RA, Mao L., Gharabawi G.Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. Schizophr Res.2004 ;66:163-167.
19.
Madhusoodanan S., Brenner R., Gupta S., et al. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr.2004 ;9:862-867.
20.
Hwang JP, Yang CH, Lee TW, Tsai SJThe efficacy and safety of olanzapine for the treatment of geriatric psychosis . J Clin Psychopharmacol. 2003;23:113-118.
21.
Jeste DV, Barak Y., Madhusoodanan S., et al. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia . Am J Geriatr Psychiatry. 2003;11:638-647.
22.
Barak Y., Shamir E., Zemishlani H., et al. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry . 2002;26:1199-1202.
23.
Breier A., Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002;52:438-445.
24.
Madhusoodanan S., Brenner R., Suresh P., et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry. 2000;12:11-18.
25.
Street JS, Tollefson GD, Tohen M., et al. Olanzapine for psychotic conditions in the elderly. Psychiatric Ann. 2000;30:191-196.
26.
Barak Y., Shamir E., Mirecki I., et al. Switching elderly chronic psychotic patients to olanzapine. Int J Neuropsychopharmacol.2004;7:165-169.
27.
McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis if Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
28.
Guy W, ed. National Institute of Mental Health. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication Adm 76-338. Washington, DC: US Department of Health, Education, and Welfare ; 1976:217-222.
29.
Folstein MF , Folstein SE, McHugh PRMini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res.1975;12:189-198.
30.
Kinon BJ, Basson BR, Gilmore JA, Tollefson GDLong-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry.2001;62:92-100.
31.
Mallinckrodt CH, Sanger TM, Dube S., et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry.2003;53:754-760.
32.
Kinon BJ, Stauffer VL, McGuire HC, et al. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients. J Am Med Dir Assoc.2003 ;4:189-194.
33.
Kinon BJ, Jeste DV, Kollack-Walker S., et al. Olanzapine treatment for tardive dyskinesia schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:985-996.
34.
Kennedy J., Deberdt W., Siegal A., et al. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. IntlJ Geriatr Psychiatry. 2005;20:1020-1027.
35.
Hennen J., Perlis RH, Sachs G., et al. Weight gain during treatment of bipolar I patients with olanzapine . J Clin Psychiatry.2004;65:1679-1687.
36.
Kawachi I.Physical and psychological consequences of weight gain. J Clin Psychiatry.1999;60(suppl 21):5-9.
37.
Bellanger TM, Bray GAObesity related morbidity and mortality. J La State Med Soc.2005;157(Spec No 1):S42-S429.
38.
Micca JL, Hoffmann VP, Lipkovich I., Ahl J., Baker RW, Hardy TARetrospective analysis of diabetes risk in elderly dementia patients in olanzapine clinical trials. Am J Geriatr Psychiatry. 2006;14:62-70.
White H., Pieper C., Schmader K.The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc.1998;46: 1223-1227.
41.
White H., McConnell ES, Bales CW, Kuchibhatla M.A 6-month observational study of the relationship between weight loss and behavioral symptoms in institutionalized Alzheimer's disease subjects. J Am Med Dir Assoc.2004;5:89-97.
42.
van Staveren WA, de Graaf C., de Groot Lcpgm.Regulation of appetite in frail persons . Clin Geriatr Med.2002;18:675-684.
43.
Keller HH, Gibbs AJ, Boudreau LD, et al. Prevention of weight loss in dementia with comprehensive nutritional treatment. J Am Geriatr Soc.2003;51:945-952.
